Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Boissart, C ^a   Poulet, A ^a   Georges, P ^a   Darville, H ^a   Julita, E ^a   Delorme, R ^b,c   Bourgeron, T ^b,d,e   Peschanski, M ^a   Benchoua, A ^a  

^a I Stem   (France)

^b INSTITUT PASTEUR   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cortical superficial layers; Disease modeling; Drug discovery; High throughput screening; Human pluripotent stem cells

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA (3,5 DICHLOROBENZYLIDENE) 3 PYRIDYLACETONITRILE; AZAPAULLONE; BML 257; CENTRAL NERVOUS SYSTEM AGENTS; CLOZAPINE; DIMETHYL SULFOXIDE; FASUDIL; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYPERICIN; KENPAULLONE; L 685 458; L 695 458; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SC 514; SU 4312; TWS 119; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; Y 26732;

ARTICLE; BIOLOGICAL ACTIVITY; BRAIN CELL; CELL ASSAY; CELL POPULATION; CELL STRUCTURE; CELLULAR PARAMETERS; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MENTAL DISEASE; MITOSIS; MOLECULAR DYNAMICS; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEURITE; PLURIPOTENT STEM CELL; AUTISM; BIOLOGICAL MODEL; BRAIN CORTEX; CELL DIFFERENTIATION; CYTOLOGY; NERVE CELL;

AUTISTIC DISORDER; CELL DIFFERENTIATION; CEREBRAL CORTEX; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, BIOLOGICAL; NEURONS; PLURIPOTENT STEM CELLS;

EID: 84883098920     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.71     Document Type: Article

References (44)

1. Marchetto MC, Winner B, Gage FH. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet 2012; 19: R71-R76.
2. Phillips BW, Crook JM. Pluripotent human stem cells: a novel tool in drug discovery. BioDrugs 2012; 24: 99-108.
3. Brennand KJ, Simone A, Tran N, Gage FH. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012; 17: 1239-1253.
4. Ferland RJ, Guerrini R. Nodular heterotopia is built upon layers. Neurology 2009; 73: 742-743.
5. Smiley JF, Rosoklija G, Mancevski B, Mann JJ, Dwork AJ, Javitt DC. Altered volume and hemispheric asymmetry of the superficial cortical layers in the schizophrenia planum temporale. Eu J Neurosci 2009; 30: 449-463.
6. Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 2010; 1309: 83-94.
7. Kwon HB, Kozorovitskiy Y, Oh WJ, Peixoto RT, Akhtar N, Saulnier JL et al. Neuroligin-1-dependent competition regulates cortical synaptogenesis and synapse number. Nat Neurosci 2012; 15: 1667-1674.
8. Marin-Padilla M. Ontogenesis of the pyramidal cell of the mammalian neocortex and developmental cytoarchitectonics: a unifying theory. J Comp Neurol 1992; 321: 223-240.
9. Hill RS, Walsh CA. Molecular insights into human brain evolution. Nature 2005; 437: 64-67. (Pubitemid 41613427)
10. Hutsler JJ, Lee DG, Porter KK. Comparative analysis of cortical layering and supragranular layer enlargement in rodent carnivore and primate species. Brain Res 2005; 1052: 71-81. (Pubitemid 41121952)
11. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008; 3: 519-532.
12. Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 2012; 153: S471.
13. Mariani J, Simonini MV, Palejev D, Tomasini L, Coppola G, Szekely AM et al. Modeling human cortical development in vitro using induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109: 12770-12775.
14. Mizutani K, Saito T. Progenitors resume generating neurons after temporary inhibition of neurogenesis by Notch activation in the mammalian cerebral cortex. Development 2005; 132: 1295-1304. (Pubitemid 40528789)
15. Rodriguez M, Choi J, Park S, Sockanathan S. Gde2 regulates cortical neuronal identity by controlling the timing of cortical progenitor differentiation. Development 2012; 139: 3870-3879.
16. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39: 25-27. (Pubitemid 46026497)
17. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnolol 2008; 26: 101-106.
18. Boissart C, Nissan X, Giraud-Triboult K, Peschanski M, Benchoua A. miR-125 potentiates early neural specification of human embryonic stem cells. Development 2012; 139: 1247-1257.
19. Rishton GM. Small molecules that promote neurogenesis in vitro. Recent Pat CNS Drug Discov 2008; 3: 200-208.
20. Hansen DV, Lui JH, Parker PR, Kriegstein AR. Neurogenic radial glia in the outer subventricular zone of human neocortex. Nature 2010; 464: 554-561.
21. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275-280.
22. Saito T, Hanai S, Takashima S, Nakagawa E, Okazaki S, Inoue T et al. Neocortical layer formation of human developing brains and lissencephalies: consideration of layer-specific marker expression. Cereb Cortex 2011; 21: 588-596.
23. Munji RN, Choe Y, Li G, Siegenthaler JA, Pleasure SJ. Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. J Neurosci 2011; 31: 1676-1687.
24. Zhang JH, Chung TD, Oldenburg KRA. Simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73. (Pubitemid 29278954)
25. Desbordes SC, Studer L. Adapting human pluripotent stem cells to highthroughput and high-content screening. Nat Protoc 2012; 8: 111-130.
26. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998; 55: 215-224.
27. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2006; 11: 557-566.
28. Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 2012; 7: 1836-1846.
29. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2012; 143: 527-539.
30. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
31. Tashiro A, Minden A, Yuste R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb Cortex 2000; 10: 927-938.
32. Wahl S, Barth H, Ciossek T, Aktories K, Mueller BK. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol 2000; 149: 263-270. (Pubitemid 30227145)
33. Lin MY, Lin YM, Kao TC, Chuang HH, Chen RH. PDZ-RhoGEF ubiquitination by Cullin3-KLHL20 controls neurotrophin-induced neurite outgrowth. J Cell Biol 2011; 193: 985-994.
34. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, EP. Henske. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002; 21: 8470-8476. (Pubitemid 36054887)
35. Ramakers GJ. Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci 2002; 25: 191-199. (Pubitemid 34615536)
36. Margolis RL, Ross CA. Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness. Neuropsychopharmacology 2010; 35: 350-351.
37. Piton A, Gauthier J, Hamdan FF, Lafreniere RG, Yang Y, Henrion E et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry 2011; 16: 867-880.
38. Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011; 4: 16.
39. Mines MA, Jope RS. Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Front Mol Neurosci. 2011; 4: 35.
40. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006; 16: 525-540. (Pubitemid 44737208)
41. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2012; 6: 407-411.
42. Bar-Nur O, Caspi I, Benvenisty N. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 2012; 4: 180-183.
43. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci USA 2011; 108: 14169-14174.
44. Mou X, Wu Y, Cao H, Meng Q, Wang Q, Sun C et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Therap 2012; 3: 14.